EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment

Jayalakshmi Thiruppathi, Veena Vijayan, Hye Suk Hwang, Yong Jun Bang, Vandara Loeurng, Seol Hee Hong, Aravindkumar Sundaram, In-Kyu Park, Shee Eun Lee, Joon Haeng Rhee

Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010272

DOI: 10.1136/jitc-2024-010272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.03.2025. Verfasst von Jayalakshmi Thiruppathi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Chonnam National University, Hwasun, Korea (the Republic of). Hauptthemen laut MEDLINE: Cancer Vaccines, Flagellin, Photothermal Therapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &Welfare, Republic of Kor…, National Research Foundation of Korea (NRF) grant funded by the Korea government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer immunotherapy, leveraging the immune system to target and eradicate cancer cells, has transformed cancer treatment paradigms. Immune checkpoint inhibitors (ICIs) are used in a wide array of cancers, but only a limited fraction of patients are responding. Cancer vaccines could elicit antigen-specific immune responses and establish long-term immune memory, preventing recurrence and metastasis. Despite their promising profiles, ICIs and cancer vaccines by themselves are often insufficient to overcome the immunosuppressive tumor microenvironment (TME) and recurrence/metastasis. Addressing these challenges is crucial for improving cancer immunotherapy outcomes.

Methods

The targeted liposomal formulation (TLIF), displaying Cyclic RGD (cRGD) peptide on the surface and encapsulating ICG and thermoresistant flagellin (FlaB) inside, was used for photothermal therapy (PTT), which was designed to induce robust immunogenic cell death (ICD) and release tumor antigens (TAs). We employed a mouse breast cancer model amenable to PTT. Utilizing a bilateral DD-Her2/neu tumor implantation model, we evaluated local and abscopal effects of combinatorial approaches employing PTT, FlaB-adjuvanted peptide vaccine (FlaB-Vax), and anti-PD-1 treatment. FlaB-Vax was designed to trigger tumor-associated antigen (TAA)-specific immune responses, which will trigger specific anti-tumor immunity. TLIF-PTT aimed to reduce tumor burden and induce ICD-mediated TA liberation for epitope spreading. Sustained anti-tumor immune memory was assessed by orthotopic rechallenging cured mice with the DD-Her2/neu tumor cells.

Results

The combination of TLIF-PTT and FlaB-Vax provided significantly enhanced primary tumor suppression, with strong abscopal effects and long-lasting immune memory. The addition of anti-PD-1 therapy further improved long-term relapse-free survival, highlighting the potential of this combinatorial approach to induce durable antitumor immunity and sustainably prevent cancer recurrence and metastasis.

Conclusion

This study demonstrates that the combination of TLIF-PTT and FlaB-Vax synergistically induced synergistic anti-tumor immune responses, which were efficaciously potentiated by anti-PD-1 treatment for recurrence-free long-term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesFlagellinPhotothermal TherapyImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorImmunotherapyAnimalsMiceFemaleHumansAdjuvants, ImmunologicCell Line, TumorCombined Modality Therapy

Stichwörter der Autor:innen

AbscopalAdjuvantBreast CancerImmune Checkpoint InhibitorVaccine

Substanzen

Cancer VaccinesFlagellinImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAdjuvants, Immunologic

Autor:innen und Institutionen

  • Chonnam National University, Hwasun, Korea (the Republic of).
  • Department of Biomedical Science,College of Life Science and Industry, Sunchon National University, Sunchon 57922, South Korea.
  • Chonnam National University, Gwangju, Korea (the Republic of).
  • Chonnam National University Medical School, Gwangju, Korea (the Republic of) jhrhee@jnu.ac.kr selee@chonnam.ac.kr pik96@jnu.ac.kr.
  • Chonnam National University, Gwangju, Korea (the Republic of) jhrhee@jnu.ac.kr selee@chonnam.ac.kr pik96@jnu.ac.kr.
  • Chonnam National University, Hwasun, Korea (the Republic of) jhrhee@jnu.ac.kr selee@chonnam.ac.kr pik96@jnu.ac.kr.

Förderung

  • Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &Welfare, Republic of Kor…
  • National Research Foundation of Korea (NRF) grant funded by the Korea government

Zitieren

APA

Thiruppathi, J., Vijayan, V., Hwang, H. S., Bang, Y. J., Loeurng, V., Hong, S. H., Sundaram, A., Park, I. K., Lee, S. E., & Rhee, J. H. (2025). Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment. Journal for ImmunoTherapy of Cancer, 13(3), e010272. https://doi.org/10.1136/jitc-2024-010272

Vancouver

Thiruppathi J, Vijayan V, Hwang HS, Bang YJ, Loeurng V, Hong SH, et al. Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010272. doi:10.1136/jitc-2024-010272

BibTeX
@article{Thiruppathi2025,
  author = {Thiruppathi, Jayalakshmi and Vijayan, Veena and Hwang, Hye Suk and Bang, Yong Jun and Loeurng, Vandara and Hong, Seol Hee and Sundaram, Aravindkumar and Park, In-Kyu and Lee, Shee Eun and Rhee, Joon Haeng},
  title = {Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {e010272},
  doi = {10.1136/jitc-2024-010272}
}
Kostenlos starten →